CHIROCAINE 5.0MG/ML SOLUTION FOR INJECTION

(-)-bupivacaine AU:B3 N01BB10(WHO) AU:S4(Prescription only)UK:POM(Prescription only)EU:Rx-only (S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide 27262-47-1YHCl:27262-48-2Y 92253HCl:117965 7211 DB01002YHCl:DBSALT000834Y 83289Y A5H73K9U3WHCl:J998RDZ51IY D08116YHCl:D01287Y CHEBI:6149N ChEMBL1201193YHCl:ChEMBLChEMBL1201177Y 8048496HCl:9046071 Interactive image O=C([C@H]1N(CCCC1)CCCC)NC2=C(C)C=CC=C2C InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1YKey:LEBVLXFERQHONN-INIZCTEOSA-NY Levobupivacaine(rINN) is alocal anaestheticdrug indicated for minor and majorsurgical anaesthesiaandpain management. It is a long-actingamide-type local anaesthetic that blocks nerve impulses by inhibiting sodium ion influx into thenerve cells.Levobupivacaine is the S-enantiomerof racemicbupivacaineand therefore similar in pharmacological effects.The drug typically starts taking effect within 15 minutes and can last up to 16 hours depending on factors such as site of administration and dosage. Levobupivacaine was designed, in the late 1970s, to be a safer and more effective alternative to bupivacaine, which had been associated with a higher risk of cardiotoxicity.Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine and has a longermotor blockonset time.Ropivacaine is, next to levobupivacaine, another less cardiotoxic alternative to bupivacaine. Levobupivacaine hydrochloride is commonly marketed byAbbVieunder thetrade nameChirocaine.In Europe, Chirocaine is available –prescription only– in concentrations ranging from 0.625 mg/mL to 7.5 mg/mL.